Medtronic PLC vs Impinj Inc — how do they compare? Medtronic PLC trades at $88.85 (market cap $112.24B), while Impinj Inc trades at $186 (market cap $5.60B). The key difference: Medtronic PLC is far larger — about 20× Impinj Inc's market cap, and Medtronic PLC pays a 3.28% dividend while Impinj Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Impinj Inc for 22 Days on average.
| MDT | PI | |
|---|---|---|
Market Cap | $112.24B | $5.60B |
Volume | 105,663,236 | 9,929 |
Sector | Health | Technology |
52-Week High | $105.35 | $241.91 |
52-Week Low | $73.75 | $91.34 |
Typical Hold Time | 63 Days | 22 Days |
Enterprise Value | $131.58B | $5.73B |
Dividend Yield | 3.28% | — |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $85.51, down 1.81% on the day, with the stock showing bearish technical signals despite strong fundamental performance. The company has beaten earnings expectations for three consecutive quarters, maintains a healthy 13.93% net income margin, and offers a solid 3.2% dividend yield with 49 consecutive years of dividend growth. Recent positive developments include FDA clearances for new medical technologies and raised full-year guidance.
MDT presents a compelling value opportunity with analyst consensus pointing to 14% upside to the $97.80 price target. The stock's current valuation multiples (P/E 21.61, P/S 3.01) appear reasonable given the company's stable revenue growth and strong cash flow generation. Key risks include increasing debt levels and competitive pressures in the medical device sector, but the company's dividend aristocrat status and improving operational performance support a positive long-term outlook.
Impinj (PI) trades at $191.04, up 3.81% with strong technical momentum and bullish moving average signals. The company shows revenue growth with Q2 2026 earnings beating estimates, though profitability remains challenged with negative net margins. Analyst consensus is strongly bullish with 16 buy ratings and a $178.83 price target, while recent news highlights the company's positioning in RFID technology and upcoming Q3 earnings.
The stock presents growth potential from expanding RFID adoption but faces risks from persistent unprofitability and high valuation multiples. Current technical strength and institutional interest support near-term upside, though investors should monitor Q3 earnings results and margin improvement for sustained momentum.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →